PURPOSE: According to the ASCO guidelines 4 cytotoxic agents are used in @entity14 . Numerous agents have not been used or tested and thus their effectiveness is not known. Herein we present the preliminary data of a trial whose objective was to investigate the effectiveness to 2 combined agents in @entity1 with heavily pretreated @entity420 . METHODS: Ten @entity1 have been recruited up until now. @entity14 was the primary disease in 7 @entity1 , @entity356 in 2, and @entity1204 in one. All @entity1 had undergone at least 2 lines of previous chemotherapy during 2-3 years before the trial. The lungs were the only or main site of metastases in all @entity1 . Chemotherapy agents used were pemetrexed 500 mg/m(2) and @entity1205 75 mg/m(2), repeated every 3 weeks, with a plan to administer 6 cycles. RESULTS: The mean number of cycles were 3 (range 1-6). Total number of cycles 33. No serious @entity137 was detected. One @entity1 had complete response, 3 partial response, 5 stable disease, 1 disease progression. Median survival was 6 months (range 2-12+ months). CONCLUSION: The effectiveness of the pemetrexed- @entity1205 combination in heavily pretreated @entity420 @entity1 justifies their use when no other alternative exists.

Metastatic lung disease treated with pemetrexed- XXXX combination chemotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial adenocarcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity14 :: ('MESH:D015179', 'Disease') :: ['Colorectal adenocarcinoma', 'colorectal cancer'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']
